Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial
Pharmacology, Toxicology and Pharmaceutical Science
2
4%
Agricultural and Biological Sciences
2
4%
Other
5
9%
Unknown
24
43%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 30. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 November 2023.
All research outputs
#1,671,239
of 34,306,620 outputs
Outputs from Journal of Clinical Oncology
#4,642
of 32,278 outputs
Outputs of similar age
#32,162
of 475,581 outputs
Outputs of similar age from Journal of Clinical Oncology
#95
of 417 outputs
Altmetric has tracked 34,306,620 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 32,278 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.2. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 475,581 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 417 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.
